Overview

To Study the Use of Humanized CD25 in Preventing the Relapse of Psoriasis Vulgaris

Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
This study is designed to study disease relapse after NBUVB and how the administration of Daclizumab/placebo alters disease relapse.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Rockefeller University
Collaborator:
Facet Biotech
Treatments:
Daclizumab
Immunoglobulin G